Global Cord Blood Corporation (CO) Reports Q3 EPS of $0.15, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021
February 24, 2021 4:16 PM ESTHONG KONG, Feb. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2021, ended December 31, 2020.
Third Quarter Fiscal 2021 Highlights
Revenues decreased by 13.1% year-over-year ("YoY") to RMB290.8 million ($44.6 million). New subscribers and accumulated subscriber base were 17,802 and 882,982[1], respectively. Gross profit decreased by 13.1% YoY to RMB245.9 million ($37.7 million). Gross... More